In the claims:

1. (currently amended) A pharmaceutical composition in the form of an orally deliverable liquid, the composition comprising water having in solution therein a pharmaceutically acceptable water-soluble salt of ~~a tolterodine related compound herein is tolterodine, (R)-N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine, its (S)-enantiomer or a racemic mixture thereof; a metabolite thereof that exhibits antimuscarinic activity, including (R)-N,N-diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropanamle (herein "hydroxytolterodine"), its (S)-enantiomer or a racemic mixture thereof; or a prodrug of tolterodine, hydroxytolterodine, thek (S) enantiomers or racemic mixtures~~ (i) tolterodine, (R)-N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine, the (S)-enantiomer thereof, or a racemic mixture thereof; (ii) a tolterodine metabolite that exhibits antimuscarinic activity, including hydroxytolterodine, (R)-N,N-diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropanamine, the (S)-enantiomer thereof, or a racemic mixture thereof; or (iii) a prodrug of tolterodine, hydroxytolterodine, or (S)-enantiomer thereof; at a therapeutically effective concentration in the composition; wherein the composition has a pH of about 2 to about 6 and further comprises a sweetening agent and an antimicrobial agent at a concentration that is antimicrobially effective at the pH of the composition.

2. (original) The composition of claim 1 that comprises means for adjusting pH to about 2 to about 5.

3. (original) The composition of claim 2 wherein the pH adjusting means comprises an acidic buffer system.

4. (previously presented) The composition of claim 1 wherein the salt has a solubility in water of at least 1 mg/ml.

5. (previously presented) The composition of claim 1 wherein the salt has a solubility in water of at least 10 mg/ml.

6. (original) The composition of claim 1 wherein the tolterodine related compound is hydroxytolterodine.

7. (original) The composition of claim 1 wherein the tolterodine related compound is tolterodine.

8. (original) The composition of claim 7 wherein the salt of tolterodine is selected from the heptanoate, caprate, laurate, edisylate, pamoate, xinafoate, 2-hydroxy-1-naphthoate, maleate, fumarate, benzoate, tartrate, hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, nitrate, citrate and mesylate salts.

9. (original) The composition of claim 7 wherein the salt of tolterodine is tolterodine tartrate.

10. (original) The composition of claim 9 wherein the concentration of tolterodine tartrate is about 0.01 to about 1 mg/ml.

11. (original) The composition of claim 9 wherein the concentration of tolterodine tartrate is about 0.05 to about 0.8 mg/ml.

12. (original) The composition of claim 9 wherein the concentration of tolterodine tartrate is about 0.1 to about 0.4 mg/ml.

13. (original) The composition of claim 7 wherein the pH is about 3 to about 5.

14. (original) The composition of claim 7 wherein the pH is about 3.5 to about 4.5.

15. (original) The composition of claim 7 that comprises an acidic buffer system effective to achieve a pH of about 3 to about 5.

16. (original) The composition of claim 7 that comprises an acidic buffer system effective to achieve a pH of about 3.5 to about 4.5.

17. (original) The composition of claim 15 wherein the acidic buffer system comprises an acidulant acid and an alkali metal salt of said acid.

18. (original) The composition of claim 15 wherein the acidic buffer system comprises an citric acid and sodium citrate.

19. (original) The composition of claim 7 wherein the antimicrobial agent is selected from the group consisting of sorbic and benzoic acids and salts thereof.

20. (original) The composition of claim 7 wherein the antimicrobial agent is sodium benzoate.

21. (original) The composition of claim 20 wherein the sodium benzoate is present in a concentration in the composition of about 0.6 to about 2 mg/ml.

22. (original) The composition of claim 20 wherein the sodium benzoate is present in a concentration in the composition of about 0.7 to about 1.5 mg/ml.

23. (original) The composition of claim 7 wherein the sweetening agent is selected from the group consisting of glucose, fructose, sucrose, xylitol, tagarose, sucralose, maltitol, isomaltulose, hydrogenated isomaltulose, lactitol, sorbitol, mannitol, trehalose, polydextrose, glycerin, erythritol, acesulfame and salts thereof, alitame, aspartame, neotame, cyclamate, saccharin and salts thereof, neohesperidin dihydrochalcone, stevioside, thaumatin, hydrogenated starch hydrolysates, high fructose corn syrup and combinations thereof.

24. (canceled)

25. (original) The composition of claim 7, further comprising a flavoring agent.

26. (original) A method of treating a muscarinic receptor mediated disorder in a subject, the method comprising orally administering to the subject a therapeutically effective dosage amount of the composition of claim 1.

27. (original) The method of claim 26 wherein the disorder is overactive bladder.

28. (original) The method of claim 26 wherein the dosage amount is not greater than about 20 ml.

29. (original) The method of claim 26 wherein the composition comprises tolterodine tartrate and the dosage amount delivers about 0.2 to about 5 mg of the tolterodine tartrate.

30. (original) The method of claim 29 wherein the dosage amount delivers about 1 to about 2 mg of the tolterodine tartrate.

31. (original) The method of claim 26 wherein the composition is administered 1 to 2 times daily.